The Experts below are selected from a list of 69 Experts worldwide ranked by ideXlab platform
George J Hanna - One of the best experts on this subject based on the ideXlab platform.
-
exploratory study comparing the metabolic toxicities of a lopinavir Ritonavir Plus Saquinavir dual protease inhibitor regimen versus a lopinavir Ritonavir Plus zidovudine lamivudine nucleoside regimen
Journal of Antimicrobial Chemotherapy, 2007Co-Authors: William D Cameron, Stephen C Becker, Martin S King, Barbara A Da Silva, Cheri E Klein, Debbie Tokimoto, Cheryl Foit, Deborah Calhoun, Barry M Bernstein, George J HannaAbstract:Results: By intent-to-treat (non-completer 5 failure) analysis, 10/16 (63%) lopinavir/Ritonavir 1 Saquinavir-treated and 7/14 (50%) lopinavir/Ritonavir 1 zidovudine/lamivudine-treated subjects achieved plasma HIV-1 RNA <50 copies/mL (P 5 0.713) at week 48. Safety, tolerability, metabolic changes and truncal fat increases were similar between groups. Small decreases in the lower extremity fat in the zidovudine/lamivudine group (‐6%) and a statistically significant increase in the lower extremity fat in the Saquinavir group (119%) were observed. Lopinavir/Ritonavir co-administered with Saquinavir 600 or 800 mg twice daily produced Saquinavir concentrations similar to those previously reported for Saquinavir/Ritonavir 1000/100 mg twice daily. Conclusions: Treatment regimens had similar efficacy and tolerability. Metabolic parameters suggested lipoatrophy in the zidovudine/lamivudine treatment group. Saquinavir 600 and 800 mg twice daily produced concentrations similar to those previously reported for Saquinavir/Ritonavir 1000/100 mg twice daily.
-
Exploratory study comparing the metabolic toxicities of a lopinavir/Ritonavir Plus Saquinavir dual protease inhibitor regimen versus a lopinavir/Ritonavir Plus zidovudine/lamivudine nucleoside regimen
Journal of Antimicrobial Chemotherapy, 2007Co-Authors: D. William Cameron, Stephen C Becker, Martin S King, Barbara A Da Silva, Cheri E Klein, Debbie Tokimoto, Cheryl Foit, Deborah Calhoun, Barry M Bernstein, George J HannaAbstract:Results: By intent-to-treat (non-completer 5 failure) analysis, 10/16 (63%) lopinavir/Ritonavir 1 Saquinavir-treated and 7/14 (50%) lopinavir/Ritonavir 1 zidovudine/lamivudine-treated subjects achieved plasma HIV-1 RNA
Brenda Dauer - One of the best experts on this subject based on the ideXlab platform.
-
the lopsaq study 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir Ritonavir Plus Saquinavir without additional antiretroviral therapy
Journal of Antimicrobial Chemotherapy, 2006Co-Authors: Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, A Carlebach, P. Gute, S Klauke, Yvonne Hermschulte, Martin Stuermer, Brenda DauerAbstract:Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of lopinavir/Ritonavir and Saquinavir ('LOPSAQ') without reverse transcriptase inhibitors (RTI) in HIV-positive patients who have few viable RTI treatment options. Methods: Cohort study of 128 heavily pre-treated patients who were experiencing therapy failure on their current regimen due to RTI resistance and/or systemic toxicities. Patients with Pi-resistance mutations or RTI toxicity underwent a structured treatment interruption (STI) (n = 76) until virus reverted to wild-type or until resolution of toxicity symptoms. Baseline was defined as the time point when lopinavir/Ritonavir Plus Saquinavir therapy was initiated. Virological response was defined as viral load <400 copies/mL at week 48. Results: A total of 78 (61%) patients experienced a virological response to therapy (ITT). Median viral load at baseline was 5.06 log 10 copies/mL; at week 48 median was 2.16 log 10 copies. Median CD4 at week 48 was 280 cells/mm 3 compared with 172 cells at baseline. At week 48, 78/128 patients were still on therapy. In univariable analyses, significant predictors of virological response included higher CD4 count (P < 0.001), lower viral load (P = 0.002), less Pi-experience (P = 0.006) at baseline and fewer Pi-resistance mutations (P = 0.043) at end of prior failing regimen; in the multivariable analysis only higher CD4 count at baseline (P = 0.009) and fewer number of drugs previously taken (P= 0.003) could be specified as independent predictors for response. Conclusions: The combination of lopinavir/Ritonavir and Saquinavir without RTIs is a potential option as salvage therapy for patients experiencing therapy failure due to RTI resistance or toxicity. This regimen may not be suitable for patients with very low baseline CD4 cell counts, very broad antiretroviral therapy experience or extensive PI-resistance mutations.
-
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/Ritonavir Plus Saquinavir without additional antiretroviral therapy
Journal of Antimicrobial Chemotherapy, 2006Co-Authors: Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, A Carlebach, P. Gute, S Klauke, Yvonne Hermschulte, Martin Stuermer, Brenda DauerAbstract:Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of lopinavir/Ritonavir and Saquinavir ('LOPSAQ') without reverse transcriptase inhibitors (RTI) in HIV-positive patients who have few viable RTI treatment options. Methods: Cohort study of 128 heavily pre-treated patients who were experiencing therapy failure on their current regimen due to RTI resistance and/or systemic toxicities. Patients with Pi-resistance mutations or RTI toxicity underwent a structured treatment interruption (STI) (n = 76) until virus reverted to wild-type or until resolution of toxicity symptoms. Baseline was defined as the time point when lopinavir/Ritonavir Plus Saquinavir therapy was initiated. Virological response was defined as viral load
William D Cameron - One of the best experts on this subject based on the ideXlab platform.
-
exploratory study comparing the metabolic toxicities of a lopinavir Ritonavir Plus Saquinavir dual protease inhibitor regimen versus a lopinavir Ritonavir Plus zidovudine lamivudine nucleoside regimen
Journal of Antimicrobial Chemotherapy, 2007Co-Authors: William D Cameron, Stephen C Becker, Martin S King, Barbara A Da Silva, Cheri E Klein, Debbie Tokimoto, Cheryl Foit, Deborah Calhoun, Barry M Bernstein, George J HannaAbstract:Results: By intent-to-treat (non-completer 5 failure) analysis, 10/16 (63%) lopinavir/Ritonavir 1 Saquinavir-treated and 7/14 (50%) lopinavir/Ritonavir 1 zidovudine/lamivudine-treated subjects achieved plasma HIV-1 RNA <50 copies/mL (P 5 0.713) at week 48. Safety, tolerability, metabolic changes and truncal fat increases were similar between groups. Small decreases in the lower extremity fat in the zidovudine/lamivudine group (‐6%) and a statistically significant increase in the lower extremity fat in the Saquinavir group (119%) were observed. Lopinavir/Ritonavir co-administered with Saquinavir 600 or 800 mg twice daily produced Saquinavir concentrations similar to those previously reported for Saquinavir/Ritonavir 1000/100 mg twice daily. Conclusions: Treatment regimens had similar efficacy and tolerability. Metabolic parameters suggested lipoatrophy in the zidovudine/lamivudine treatment group. Saquinavir 600 and 800 mg twice daily produced concentrations similar to those previously reported for Saquinavir/Ritonavir 1000/100 mg twice daily.
-
improvement in cell mediated immune function during potent anti human immunodeficiency virus therapy with Ritonavir Plus Saquinavir
The Journal of Infectious Diseases, 1998Co-Authors: Jonathan B Angel, Ashok Kumar, Karl Parato, Lionel G Filion, Francisco Diazmitoma, Pirouz Daftarian, Ba Pham, John M Leonard, William D CameronAbstract:Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4 + lymphocyte count. The effect of combination protease inhibitor therapy (Ritonavir Plus Saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log 10 copies/mL to below the detection limit of the assay (2.30 log 10 ), and mean CD4 + lymphocyte count increased from 284 cells/μL to 413 cells/μL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8 + lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process.
D M Burger - One of the best experts on this subject based on the ideXlab platform.
-
lopinavir Ritonavir Plus Saquinavir in salvage therapy pharmacokinetics tolerability and efficacy
AIDS, 2003Co-Authors: C J L La Porte, Janchristian Wasmuth, K Schneider, J K Rockstroh, D M BurgerAbstract:Patients receiving a lopinavir/Ritonavir and Saquinavir dual protease inhibitor-based antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability and efficacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and Saquinavir. Patient records were studied for adverse events and efficacy data. The pharmacokinetics of lopinavir and Saquinavir were comparable with literature data, except for the Saquinavir 0-12 h area under the curve and maximum concentration. The tolerability of the regimen was good and efficacy was encouraging.
-
Lopinavir/Ritonavir Plus Saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.
AIDS, 2003Co-Authors: C J L La Porte, Janchristian Wasmuth, K Schneider, J K Rockstroh, D M BurgerAbstract:Patients receiving a lopinavir/Ritonavir and Saquinavir dual protease inhibitor-based antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability and efficacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and Saquinavir. Patient records were studied for adverse events and efficacy data. The pharmacokinetics of lopinavir and Saquinavir were comparable with literature data, except for the Saquinavir 0-12 h area under the curve and maximum concentration. The tolerability of the regimen was good and efficacy was encouraging.
Schlomo Staszewski - One of the best experts on this subject based on the ideXlab platform.
-
the lopsaq study 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir Ritonavir Plus Saquinavir without additional antiretroviral therapy
Journal of Antimicrobial Chemotherapy, 2006Co-Authors: Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, A Carlebach, P. Gute, S Klauke, Yvonne Hermschulte, Martin Stuermer, Brenda DauerAbstract:Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of lopinavir/Ritonavir and Saquinavir ('LOPSAQ') without reverse transcriptase inhibitors (RTI) in HIV-positive patients who have few viable RTI treatment options. Methods: Cohort study of 128 heavily pre-treated patients who were experiencing therapy failure on their current regimen due to RTI resistance and/or systemic toxicities. Patients with Pi-resistance mutations or RTI toxicity underwent a structured treatment interruption (STI) (n = 76) until virus reverted to wild-type or until resolution of toxicity symptoms. Baseline was defined as the time point when lopinavir/Ritonavir Plus Saquinavir therapy was initiated. Virological response was defined as viral load <400 copies/mL at week 48. Results: A total of 78 (61%) patients experienced a virological response to therapy (ITT). Median viral load at baseline was 5.06 log 10 copies/mL; at week 48 median was 2.16 log 10 copies. Median CD4 at week 48 was 280 cells/mm 3 compared with 172 cells at baseline. At week 48, 78/128 patients were still on therapy. In univariable analyses, significant predictors of virological response included higher CD4 count (P < 0.001), lower viral load (P = 0.002), less Pi-experience (P = 0.006) at baseline and fewer Pi-resistance mutations (P = 0.043) at end of prior failing regimen; in the multivariable analysis only higher CD4 count at baseline (P = 0.009) and fewer number of drugs previously taken (P= 0.003) could be specified as independent predictors for response. Conclusions: The combination of lopinavir/Ritonavir and Saquinavir without RTIs is a potential option as salvage therapy for patients experiencing therapy failure due to RTI resistance or toxicity. This regimen may not be suitable for patients with very low baseline CD4 cell counts, very broad antiretroviral therapy experience or extensive PI-resistance mutations.
-
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/Ritonavir Plus Saquinavir without additional antiretroviral therapy
Journal of Antimicrobial Chemotherapy, 2006Co-Authors: Schlomo Staszewski, Errol Babacan, Christoph Stephan, Annette Haberl, A Carlebach, P. Gute, S Klauke, Yvonne Hermschulte, Martin Stuermer, Brenda DauerAbstract:Objectives: To evaluate the virological, immunological and clinical responses to the boosted double protease inhibitor (PI) regimen combination of lopinavir/Ritonavir and Saquinavir ('LOPSAQ') without reverse transcriptase inhibitors (RTI) in HIV-positive patients who have few viable RTI treatment options. Methods: Cohort study of 128 heavily pre-treated patients who were experiencing therapy failure on their current regimen due to RTI resistance and/or systemic toxicities. Patients with Pi-resistance mutations or RTI toxicity underwent a structured treatment interruption (STI) (n = 76) until virus reverted to wild-type or until resolution of toxicity symptoms. Baseline was defined as the time point when lopinavir/Ritonavir Plus Saquinavir therapy was initiated. Virological response was defined as viral load
